Epizyme, Inc. (EPZM) Upgraded at BidaskClub
BidaskClub upgraded shares of Epizyme, Inc. (NASDAQ:EPZM) from a sell rating to a hold rating in a report issued on Thursday.
A number of other analysts have also weighed in on the company. Leerink Swann restated an outperform rating and set a $28.00 target price (down previously from $31.00) on shares of Epizyme in a report on Wednesday, August 9th. HC Wainwright reiterated a buy rating on shares of Epizyme in a report on Monday, August 7th. Royal Bank Of Canada set a $20.00 price objective on Epizyme and gave the company a buy rating in a report on Saturday, August 5th. Zacks Investment Research upgraded Epizyme from a hold rating to a buy rating and set a $16.00 price objective for the company in a report on Tuesday, July 18th. Finally, ValuEngine upgraded Epizyme from a sell rating to a hold rating in a report on Saturday, June 24th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $23.38.
Shares of Epizyme (NASDAQ EPZM) opened at 16.50 on Thursday. The company’s market cap is $964.69 million. The company’s 50-day moving average price is $13.73 and its 200 day moving average price is $14.67. Epizyme has a one year low of $7.02 and a one year high of $18.50.
Epizyme (NASDAQ:EPZM) last posted its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.08. The company had revenue of $10 million during the quarter, compared to analyst estimates of $3.95 million. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. Epizyme’s revenue was up 2027.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.49) earnings per share. On average, equities research analysts anticipate that Epizyme will post ($2.39) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://theolympiareport.com/2017/08/27/epizyme-inc-epzm-upgraded-at-bidaskclub-2.html.
In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction on Monday, June 26th. The stock was sold at an average price of $14.87, for a total value of $223,050.00. Following the completion of the transaction, the insider now owns 22,228 shares in the company, valued at approximately $330,530.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Robert A. Copeland sold 2,500 shares of the firm’s stock in a transaction on Tuesday, June 6th. The stock was sold at an average price of $13.45, for a total value of $33,625.00. Following the completion of the transaction, the insider now owns 34,038 shares of the company’s stock, valued at approximately $457,811.10. The disclosure for this sale can be found here. In the last quarter, insiders have sold 35,524 shares of company stock valued at $505,147. Company insiders own 25.20% of the company’s stock.
A number of institutional investors have recently modified their holdings of the company. Legal & General Group Plc raised its position in shares of Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares during the period. UBS Asset Management Americas Inc. purchased a new position in shares of Epizyme during the first quarter worth about $175,000. BB&T Securities LLC purchased a new position in shares of Epizyme during the second quarter worth about $181,000. Trexquant Investment LP purchased a new position in shares of Epizyme during the second quarter worth about $184,000. Finally, SG Americas Securities LLC raised its position in shares of Epizyme by 83.3% in the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 6,072 shares during the period. Institutional investors own 81.24% of the company’s stock.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.